Document Detail

The place of accelerated schedules for hepatitis A and B vaccinations.
MedLine Citation:
PMID:  12921484     Owner:  NLM     Status:  MEDLINE    
The availability of accelerated schedules of vaccination, as well as the development of combination vaccines, has enhanced the methods of protection against infectious disease, in particular that of hepatitis A and B viruses. The benefits of using accelerated schedules include: (i) enhanced adherence to and subsequent completion of vaccine courses; (ii) convenience for the recipient of the vaccine; (iii) reduced administration costs of providing the vaccine; and, most importantly, (iv) the ability to provide protection against these serious infections to those who will be imminently exposed to the risk and so require protection as quickly as possible. Active immunisation against both hepatitis A and B viruses has only been recognised within the last 20 years. During this time clinical studies have demonstrated the safety and efficacy of administering the monovalent hepatitis B vaccine by way of accelerated schedules. There are now several accelerated schedules of administration of hepatitis B vaccine which can be tailored to the needs of the individual at risk of exposure to infection. One such schedule allows the primary course to be administered within a period of 1 month. This schedule of day 0, 7 and 21, with a booster at 12 months, is licensed for use with the recombinant hepatitis B vaccine Engerix B and results in a seroprotection rate of 65% at day 28 which increases to 99% at month 13. In more recent years, the development of a multivalent or combination vaccine against hepatitis A and B (Twinrix) has been a welcome advance in the protection against viral hepatitis, and has been of particular benefit to those who are at risk of infection with both viruses. The advantages of accelerated schedules have also been recognised with this combination vaccine. The primary course may be administered within a period of 1 month so providing protection for those at risk and, in particular, the last minute traveller.
Jane Zuckerman
Related Documents :
10835094 - Prolonged hepatitis b surface antigenemia after vaccination.
9178394 - Inflammatory joint disease after immunizations. a report of two cases.
12540504 - Trends in the incidence of hepatocellular carcinoma in boys and girls in taiwan after l...
1658214 - Further evaluation of a live hepatitis a vaccine in marmosets.
17950824 - Vaccination of biological cellulose fibers with glucose: a gateway to novel nanocomposi...
15917134 - The detection and characterisation of dichelobacter nodosus from cases of ovine footrot...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  63     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2003  
Date Detail:
Created Date:  2003-08-18     Completed Date:  2004-02-10     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1779-84     Citation Subset:  IM    
Academic Centre for Travel Medicine & Vaccines, Royal Free & University College Medical School, Rowland Hill Street, London NW3 2PF, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Hepatitis A / prevention & control
Hepatitis A Antibodies / blood
Hepatitis A Vaccines / administration & dosage*,  immunology
Hepatitis B / prevention & control
Hepatitis B Antibodies / blood
Hepatitis B Vaccines / administration & dosage*,  immunology
Immunization Schedule*
Patient Compliance
Risk Factors
Vaccines, Combined
Reg. No./Substance:
0/Hepatitis A Antibodies; 0/Hepatitis A Vaccines; 0/Hepatitis B Antibodies; 0/Hepatitis B Vaccines; 0/Vaccines, Combined; 0/twinrix

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exposure to maternal depression and marital conflict: gender differences in children's later mental ...
Next Document:  New molecular targets for treatment of peptic ulcer disease.